EN DE

Delota Corp (SYDRF) Fair Value & Analysis

Healthcare · US · Market cap $2.9M

DC Delota Corp logo Delota Corp SYDRF · US
Price$0.1000
Fair Value$0.2300
Upside+130.0%
Quality56/100
Watch Delota Corp for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 1.5% net margin
Low debt · generates free cash flow
Ranks above peers (8/12)
Narrow moat 38/100
Evidence: High Range $0.2200 – $0.2900 Share as image

Fair value as of: Jul 31, 2026

From 24 valuation models · updated 11 days ago

A solid business, screening 130% undervalued on our models.

What matters now

  • The price is below even our cautious bear case ($0.2200). The market is more pessimistic than our downside scenario.
  • Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$0.2332 $0.0400 Fair Value $0.2300 Oct 2021 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.

How to read this chart

57‑month range $0.0400 – $0.2332 · fair‑value band $0.2200 – $0.2900 · the $0.1000 price screens below the $0.2300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 31, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Delota Corp (SYDRF) currently trades at $0.1000, while our model-based Fair Value estimate is $0.2300, implying the stock looks roughly 130.0% undervalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Delota Corp generated revenue of $39.9M at a net margin of 1.5%. Revenue grew 1.2% year over year. It earns a return on equity of 71.5%. Net debt stands at $4.2M. Fundamentals as of Jul 31, 2026

Our scenario range runs from $0.2200 (bear case) to $0.2900 (bull case); at $0.1000, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 25% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at 130%, SYDRF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF $0.9600 $1.51 $2.37 80
Rev-Margin DCF $0.5500 $0.7700 $1.24 74
ROIC Compounder $0.1800 $0.1900 $0.2000 72
All 24 models by family
DCF Models
FCF DCF $1.03 $1.41 $2.52 38
Owner Earnings $0.7900 $1.47 $2.67 31
5Y Revenue Exit $0.5200 $0.6800 $1.01 39
5Y EBITDA Exit $0.8600 $1.37 $2.37 41
5Y P/E Exit $0.6100 $1.04 $1.58 38
10Y Revenue Exit $0.7000 $1.09 $1.23 36
10Y EBITDA Exit $0.9200 $1.71 $3.02 37
10Y P/E Exit $0.7600 $1.25 $1.98 35
Earnings-Based
Graham-Dodd $0.1300 $0.9200 $1.28 54
Lynch FV $0.4700 $0.6800 $0.8800 50
PEG = 1.0 $0.4700 $0.6800 $0.8800 46
EPV $0.1800 $0.1900 $0.2000 59
Multiples
P/E Multiple $0.3000 $0.4100 $0.5100 63
P/S Multiple $0.2500 $0.3300 $0.4100 58
P/B Multiple $0.1700 $0.2200 $0.2800 55
EV/EBIT $0.2900 $0.3600 $0.4300 53
EV/EBITDA $0.7600 $0.9900 $1.22 54
EV/Revenue $0.2300 $0.2900 $0.3600 43
Asset-Based
NCAV (Graham) $0.0200 $0.0300 $0.0400 50
Growth DCF
Growth DCF $0.9600 $1.51 $2.37 80
Rev-Margin DCF $0.5500 $0.7700 $1.24 74
Economic Profit
Residual Income $0.1200 $0.1900 $2.20 61
ROIC Compounder $0.1800 $0.1900 $0.2000 72
Growth Earnings
Growth-Adj P/E $0.6200 $0.8800 $1.15 68

Widest divergence: DCF Models ($1.25) versus Asset-Based ($0.0300). Highest evidence: Growth DCF (80).

Notify me when SYDRF reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $39.9M
Revenue growth (YoY) +1.2%
Net margin 1.5%
Return on equity 71.5%
Free cash flow $2.3M FY2025
P/E ratio 10.0
More key figures
Operating margin -4.2%
EPS (TTM) $0.0100
Net debt $4.2M FY2025

Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 56/100

Of which business quality 56 · Market factors (momentum, volatility) 70

Profitability 71
Margins and returns on capital today
Quality Growth 83
Are margins and returns improving?
Cashflow 65
Earnings quality: real cash, not paper profit
Fin. Strength 30
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 92
Calm price path (market factor)
Momentum 50
Price trend over the last 3–12 months (market factor)
52W Momentum 81
Distance to the 52-week high (market factor)
Net Issuance 5
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Delota Corp. engages in the retail of various cannabis products in Canada. The company provides nicotine vape and alternative tobacco products. It sells its products through specialty vape stores under the 180 Smoke Vape Store brand e-commerce platform comprising www.180smoke.ca; and dispensaries under the Offside Cannabis brand.

Full company description

Delota Corp. engages in the retail of various cannabis products in Canada. The company provides nicotine vape and alternative tobacco products. It sells its products through specialty vape stores under the 180 Smoke Vape Store brand e-commerce platform comprising www.180smoke.ca; and dispensaries under the Offside Cannabis brand. The company was formerly known as Spyder Cannabis Inc. and changed its name to Delota Corp. in November 2021. Delota Corp. is based in Concord, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Delota Corp reported revenue of $40.2M in FY2025 versus $1.3M in FY2021, a compound +136.9%/yr. Reported net income was $562K in FY2025.

Growth Quality 82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
$40.2M
Latest YoY
+18.0%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+31.5%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+134.1%
Avg. growth/yr (8Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+69.1%
Revenue +136.9%/yr
FY21 $1.3M
FY22 $17.7M
FY23 $25.9M
FY24 $34.1M
FY25 $40.2M
Net income
FY21 −$1.3M
FY22 −$8.8M
FY23 $7.7M
FY24 −$2.0M
FY25 $562K

Watch SYDRF: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Delota Corp · Fair Value
$0.2300 +130%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Delota Corp Fair Value". https://www.fairvalue-calculator.com/stock/SYDRF

Peer Group

Pharmaceutical Retailers · 62 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 56 · Above median
Fair Value upside +130% · Top 25%
Return on equity (TTM) 72% · Top 25%
Return on assets 5% · Top 25%
Net margin (TTM) 2% · Above median
Operating margin (TTM) -4% · Bottom 25%
Revenue growth 1% · Below median
Debt / equity 0.10× · Higher than median

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 10.0× · Cheaper than 75% of peers
P/B 2.45× · Pricier than median
P/S (TTM) 0.07× · Cheaper than 75% of peers
P/FCF 1.2× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 21
FUTURE 6 · sector 18
PAST 100 · sector 18
HEALTH 95 · sector 97
DIVIDEND 0 · sector 63

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc 6618 HK$39.20 HK$33.28 -15%
Raia Drogasil S.A RADL3 R$18.20 R$15.58 -14%
Yifeng Pharmacy Chain Co 603939 ¥23.43 ¥29.07 +24%
DaShenLin Pharmaceutical Group 603233 ¥18.23 ¥23.86 +31%
Corporativo Fragua, S.A. FRAGUAB 463.00 MXN 821.18 MXN +77%
LBX Pharmacy Chain Joint Stock Company 603883 ¥12.74 ¥10.57 -17%
MedPlus Health Services Limited MEDPLUS ₹690.20 ₹379.25 -45%
Yixintang Pharmaceutical Group 002727 ¥11.46 ¥9.45 -18%
Anhui Huaren Health Pharmaceutical Co 301408 ¥14.40 ¥10.05 -30%
Apotea AB APOTEA kr 74.75 kr 43.95 -41%

Compare Delota Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Delota Corp (SYDRF) overvalued or undervalued?
As of Jul 31, 2026, our model estimates a fair value of $0.2300 versus a price of $0.1000, about +130% (undervalued).
What is the fair value of SYDRF?
Our model-based fair value for Delota Corp is $0.2300 (as of Jul 31, 2026), built from audited fundamentals. The current price is $0.1000.
What is the quality score of SYDRF?
Delota Corp has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Delota Corp (SYDRF)?
Delota Corp reported trailing-twelve-month revenue of about $39.9M (latest available figure, as of Jul 31, 2026).
What is the net profit margin of SYDRF?
The net profit margin of Delota Corp is about 1.5%, meaning it keeps roughly 1.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Delota Corp and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.